3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
Radiotherapy
9
Doxorubicin
7
pazopanib
5
palbociclib
4
Trabectedin
4
Gemcitabine
4
ribociclib
3
pembrolizumab
3
eribulin
3
Magnetic Resonance Spectroscopy
3
selinexor
2
liposomal doxorubicin
2
avelumab
2
abemaciclib
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Immunoglobulin G
2
Ifosfamide
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
sotigalimab
1
sodium thiosulfate
1
sitravatinib
1
silmitasertib
1
sargramostim
1
romidepsin
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liposarcoma
×
olaparib
×
Clear all
NCT06116578
2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Withdrawn